Global Infectious Disease Testing Kits Market Size By Type (Molecular Diagnostic Test, POCT), By Application (HIV, Respiratory), By Region, And Segment Forecasts, 2023 to 2032

The Global Infectious Disease Testing Kits Market was valued at USD 25.6 billion in 2023 and is projected to surpass USD 45.3 billion by 2031, growing at a CAGR of 7.2% during the forecast period of 2023-2031. The market is driven by the increasing prevalence of infectious diseases, rising demand for rapid and accurate diagnostic solutions, and technological advancements in testing methodologies. The COVID-19 pandemic accelerated the adoption of infectious disease testing kits, leading to increased investments in research and development to enhance diagnostic accuracy and accessibility.

The growing focus on early disease detection, along with the expansion of healthcare infrastructure in emerging economies, is expected to fuel the market growth. The shift towards point-of-care testing (POCT) and the rising adoption of molecular diagnostics further contribute to the increasing demand for infectious disease testing kits worldwide.

Drivers:

1. Rising Prevalence of Infectious Diseases

The increasing incidence of infectious diseases such as HIV, tuberculosis (TB), hepatitis, respiratory infections, and sexually transmitted infections (STIs) is a significant driver for market growth. Emerging and re-emerging infectious diseases necessitate robust diagnostic solutions for effective disease management.

2. Advancements in Diagnostic Technologies

Innovations such as molecular diagnostics, polymerase chain reaction (PCR) testing, nucleic acid amplification tests (NAATs), and next-generation sequencing (NGS) have significantly improved the accuracy and speed of infectious disease diagnosis. Additionally, advancements in AI-driven diagnostics are improving disease detection efficiency.

3. Rising Demand for Point-of-Care Testing (POCT)

The increasing preference for rapid and decentralized testing solutions is propelling the demand for POCT kits, allowing faster results and improving disease control strategies.

4. Government Initiatives and Funding

Governments and healthcare organizations are actively investing in disease surveillance programs, diagnostic infrastructure, and research projects to strengthen infectious disease testing capabilities.

Restraints:

1. High Costs of Advanced Testing Kits

Molecular diagnostics and advanced testing technologies require substantial investments, making them expensive, especially for low-income regions. The affordability of PCR and NGS-based diagnostics remains a challenge for mass adoption.

2. Regulatory Challenges and Approval Processes

Strict regulatory frameworks and lengthy approval processes for diagnostic kits can hinder the market growth, delaying the launch of new and innovative products.

3. Shortage of Skilled Professionals

Despite technological advancements, the lack of trained personnel in diagnostic laboratories, particularly in developing countries, limits the widespread adoption of complex infectious disease testing methodologies.

Opportunity:

1. Expansion of Testing Services in Emerging Markets

The increasing investments in healthcare infrastructure in Asia-Pacific, Latin America, and Africa present lucrative opportunities for market players to expand their presence in developing economies.

2. Development of Rapid & At-Home Testing Kits

The rising demand for self-testing kits, such as home-based HIV, COVID-19, and influenza tests, is driving market innovation, making diagnostics more accessible to consumers.

3. Integration of AI & Digital Health Technologies

AI-driven analytics and telehealth integration are enhancing diagnostic capabilities, allowing faster result interpretation and remote consultation, which will further accelerate market adoption.

Market by System Type Insights:

Based on system type, the Molecular Diagnostics Segment accounted for the largest market share in 2023. Molecular diagnostics, including PCR, NAATs, and NGS, have gained widespread acceptance due to their high accuracy and efficiency in detecting infectious diseases. The rapid testing segment is expected to witness significant growth, driven by the increasing adoption of lateral flow assays (LFAs) and POCT solutions.

Market by End-Use Insights:

1. Hospitals & Diagnostic Laboratories (Largest Segment in 2023)

Hospitals and diagnostic laboratories remain the largest end-users of infectious disease testing kits, with increasing patient admissions, diagnostic screenings, and government-driven surveillance programs contributing to the segment’s dominance.

2. Homecare & Point-of-Care Testing (Fastest Growing Segment)

The homecare and POCT segment is witnessing significant growth due to the rising preference for at-home diagnostic solutions, advancements in self-testing technologies, and increasing consumer awareness.

Market by Regional Insights:

North America dominated the market in 2023, accounting for the largest revenue share, driven by advanced healthcare infrastructure, high adoption of diagnostic technologies, and strong government support for disease surveillance programs.

Asia-Pacific is expected to witness the highest CAGR during the forecast period, fueled by increasing investments in healthcare infrastructure, rising prevalence of infectious diseases, and growing adoption of POCT solutions in countries like China, India, and Japan.

Europe holds a significant market share, supported by government-led initiatives for disease control and advanced diagnostic laboratories.

Competitive Scenario:

Key players operating in the Global Infectious Disease Testing Kits Market include:

Abbott Laboratories

Roche Diagnostics

Siemens Healthineers

Thermo Fisher Scientific

Bio-Rad Laboratories

BD (Becton, Dickinson and Company)

Cepheid (Danaher Corporation)

Qiagen N.V.

Hologic, Inc.

PerkinElmer, Inc.

These companies are focusing on product innovation, strategic partnerships, and geographical expansion to strengthen their market positions.

Key Market Developments:

2023: Roche Diagnostics launched a new AI-powered infectious disease testing platform to enhance diagnostic accuracy.

2024: Abbott Laboratories introduced next-generation rapid POCT solutions for COVID-19 and influenza.

2025: Thermo Fisher Scientific acquired a molecular diagnostics company to expand its infectious disease testing portfolio.

Scope of Work – Global Infectious Disease Testing Kits Market